What is the latest price of Bosutinib/Bosutinib in China?

Bosutinib is an oral tyrosine kinase inhibitor for chronic myelogenous leukemia (CML). It inhibits the kinase activity of BCR-ABL fusion protein, thereby effectively preventing the proliferation and growth of cancer cells. Bosutinib is particularly suitable for CML patients who are ineffective or resistant to other treatments, providing a new clinical treatment option. Although its efficacy has been confirmed in multiple clinical studies, the drug is not currently available in China, so price information in the domestic market remains unclear.

In overseas markets, the price of the original drug of bosutinib varies greatly. For example, the Turkish version of bosutinib (500mg*28 tablets per box) may be priced at more than 2,000 yuan, which is relatively affordable. The price of the European and Swiss versions of bosutinib is as high as more than 20,000 yuan, which is a considerable expense for many patients. In addition, due to exchange rate fluctuations, actual drug prices may change, so patients need to pay attention when making choices.

In addition to the original drug, there are also a variety of bosutinib generic drugs on the international market, mainly produced by some pharmaceutical companies in India and other countries. The ingredients of these generic drugs are basically the same as those of the original drugs, and their efficacy and safety are usually guaranteed. For example, the generic version of bosutinib produced by a pharmaceutical factory in India is 100mg*120 tablets per box, priced at more than 1,000 yuan, which is more affordable than the original drug. This allows patients with limited economic conditions to have more choices in treatment options.

For patients who need to use bosutinib, although price is an important consideration, safety, effectiveness and the professional advice of doctors are also crucial when choosing a drug.

Reference materials:https://go.drugbank.com/drugs/DB06616